Precision Medicine in Oncology®

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

Single-agent cisplatin did not lead to significantly higher pathologic complete response rates or improved residual cancer burden scores compared with doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with stage I to III HER2-negative breast cancer who harbor BRCA mutations.

Andrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.

Larotrectinib continued to show strong tumor-agnostic efficacy in patients with TRK fusion–positive cancers, according to results from an integrated analysis of 3 clinical trials.

Hatim Husain, MD, discusses the increased use of and challenges with utilizing liquid biopsies.

Researchers at the Mayo Clinic maintain that all women aged 65 or under with a breast cancer diagnosis should receive germline genetic testing to identify harmful mutations that increase their risk of developing secondary cancers.

Jonathan W. Goldman, discusses the impact of liquid biopsies in lung cancer.

Patients with breast cancer who are ultrarapid or poor CYP2D6 metabolizers of tamoxifen have a worse prognosis compared with normal metabolizers after receiving a standard dose of the drug, due, in part, to a higher incidence of treatment-related adverse events.

Jonathan W. Goldman, MD, discusses the current landscape of biomarker-driven lung cancer.

Jean Lopategui, MD, associate professor of pathology and director of Translational Genomics and of the Molecular Genetics Pathology Fellowship at Cedars-Sinai, discusses the implications of genomic sequencing in lung cancer.

Hatim Husain, MD, discusses the current state of liquid biopsy in non–small cell lung cancer.

Bradley McGregor, MD, discusses enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.

Brian M. Wolpin, MD, MPH, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas study.

Julie R. Brahmer, MD, discusses targeted treatments for patients with oncogene-driven non–small cell lung cancer.

Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, director of Translational Research, and physician, Dana-Farber Cancer Institute, discusses the potential use of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Results from a first-in-human study into ABBV-621, a TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist, highlight the potential of focusing on TRAIL.

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine and a member of the Duke Cancer Institute, discusses the potential of AR-V7 as a predictive biomarker of response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Daniel F. Hayes, MD, discusses the potential of liquid biopsies in breast and other cancers and highlights some major challenges that keep these tests from wider use.

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Alexander Leandros Lazarides, MD, resident at Duke University Medical Center, discusses CRM1 as a potential target in osteosarcoma.